We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...

Pengana’s James McDonald is tipping into Aussie names Telix and Opthea, potash producer K+S, and the valuation case for Ardent at 70¢. The Carlyle Group and its newly acquired life sciences arm ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on OPT stock, giving a Buy rating yesterday.Invest with Confidence: ...

Opthea Limited (NASDAQ:OPT – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $5.49, but opened at $5.68. Opthea shares last traded at $5.65, with a ...

Check the time stamp on this data. Updated AI-Generated Signals for Opthea Limited (OPT) available here: OPT. Type a few ...

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage ...

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage ...